상세 보기
Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
- Yang, J. C-H.;
- Kim, Y. J.;
- Lee, S-H.;
- Liu, B.;
- Ostapenko, Y. V.;
- 외 15명
Citations
WEB OF SCIENCE
37- 제목
- Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
- 저자
- Yang, J. C-H.; Kim, Y. J.; Lee, S-H.; Liu, B.; Ostapenko, Y. V.; Lu, S.; Alip, A.; Korbenfeld, E. p.; Dias, J.; Danchaivijitr, P.; Girard, N.; Felip, E.; Hayashi, H.; Spira, A.; Besse, B.; Sun, T.; Ennis, M.; Sethi, S.; Bauml, J. M.; Cho, B. C.
- 발행일
- 2025-03
- 유형
- Meeting Abstract
- 권
- 20
- 호
- 3
- 페이지
- S6 ~ S8